866-997-4948(US-Canada Toll Free)

Brain Metastasis - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 65 Pages


Global Markets Directs, \'Brain Metastasis Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Brain Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Metastasis. 

Brain Metastasis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Brain Metastasis.
  • A review of the Brain Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Brain Metastasis pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Brain Metastasis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Brain Metastasis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Brain Metastasis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Brain Metastasis 8
Brain Metastasis Therapeutics under Development by Companies 10
Brain Metastasis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Brain Metastasis Therapeutics - Products under Development by Companies 16
Brain Metastasis Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Brain Metastasis Therapeutics Development 18
F. Hoffmann-La Roche Ltd. 18
Cell Therapeutics, Inc. 19
Spectrum Pharmaceuticals, Inc. 20
Philogen S.p.A. 21
Brain Metastasis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
paclitaxel poliglumex - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
lucanthone hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
veliparib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
memantine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
cediranib maleate + Whole Brain Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Patupilone - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
bendamustine hydrochloride + Fractionated Stereotactic Radiotherapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
trastuzumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
L19-I131 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drug For Glioblastoma And Brain Metastatized Systemic Cancers - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GRN-1005 + trastuzumab + 18F-Fluorothymidine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Brain Metastasis Therapeutics - Drug Profile Updates 46
Brain Metastasis Therapeutics - Discontinued Products 52
Brain Metastasis Therapeutics - Dormant Products 53
Brain Metastasis - Product Development Milestones 54
Featured News & Press Releases 54
Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer 54
Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC 55
Jun 27, 2011: to-BBB Starts Clinical Trial In Patients With Brain Metastases 57
Jun 07, 2010: Angiochem Presents Complete Phase I/II Clinical Data Of ANG1005 For Treatment Of Brain Metastases 57
May 27, 2010: YM BioSciences Enrolls First US Patient In Phase II Randomized, Double-Blind Brain Metastases Trial For Nimotuzumab 58
May 27, 2010: YM BioSciences Enrolls First US Patient In Phase II Brain Metastases Trial For Nimotuzumab 59
Apr 22, 2010: Celtic Pharma Initiates Pediatric Dose Tolerance Trial Evaluating XERECEPT In Pediatric Patients With Primary And Metastatic Brain Tumors 60
Apr 19, 2010: Celtic Pharma Announces Preclinical Findings That Xerecept Potentiates Significantly Tumor Inhibition Activity Of Avastin 60
Mar 15, 2010: Two Posters On Nimotuzumab Accepted For Presentation At AACR 61
Jan 26, 2010: YM Receives FDA Clearance For Two Ongoing Phase II Nimotuzumab Trials In US 62

Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Table


Number of Products Under Development for Brain Metastasis, H1 2013 8
Products under Development for Brain Metastasis - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 17
F. Hoffmann-La Roche Ltd., H1 2013 18
Cell Therapeutics, Inc., H1 2013 19
Spectrum Pharmaceuticals, Inc., H1 2013 20
Philogen S.p.A., H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 27
Brain Metastasis Therapeutics - Drug Profile Updates 46
Brain Metastasis Therapeutics - Discontinued Products 52
Brain Metastasis Therapeutics - Dormant Products 53

List of Chart


Number of Products under Development for Brain Metastasis, H1 2013 8
Products under Development for Brain Metastasis - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Route of Administration, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Molecule Type, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *